Direct-acting antivirals affects B cells secreting platelet-specific autoantibody in patients with chronic hepatitis C.

Direct-acting antivirals affects B cells secreting platelet-specific autoantibody in patients with chronic hepatitis C. - Direct-acting antivirals affects B cells secreting platelet-specific autoantibody

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030968

Enrollment

Registered

2018-02-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

adminstraion of direct-acting antivirals affects

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Chronic hepatitis or cirrhosis patients with HCV (2) Patients with 20 years of age and older

Exclusion criteria

Exclusion criteria: (1) Decompensated cirrhosis, Liver failure (2)patients with hepatic cell carcinoma (3) Co-infection with hepatitis B virus Co-infection with anti- humanimmunodeficiency virus

Design outcomes

Primary

Measure	Time frame
the change of B cells secreting platelet-specific autoantibody after adminstraion of direct-acting antivirals affects	—

Countries

Japan

Contacts

Public ContactHaruki Uojima

Kitasato University School of Medicine Department of Gastroenterology

kiruha@kitasato-u.ac.jp+81-42-778-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026